Overview of Dr. Lentzsch
Dr. Suzanne Lentzsch is a hematologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and NewYork-Presbyterian/Lawrence Hospital. She received her medical degree from Humboldt University of Berlin- Charite Faculty of Medicine and has been in practice 27 years. Dr. Lentzsch accepts several types of health insurance, listed below. She is one of 64 doctors at New York-Presbyterian Hospital and one of 25 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Hematology. She has more than 100 publications and over 500 citings.
Office
622 W 168th St
New York, NY 10032Fax+1 212-305-6762
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2001
- Humboldt University School of MedicinePh.D, Cum Laude, 1990 - 1994
- Humboldt University of Berlin - Charite Faculty of MedicineClass of 1990
Certifications & Licensure
- NY State Medical License 2011 - 2025
- PA State Medical License 2006 - 2024
Awards, Honors, & Recognition
- Woman of the year Candidate Leukemia Lymphoma Society, 2014
- Laugh for Life Honorary Chair MMRF, 2014
- Leukemia Diploma For a selection of worthy articles in 2012/2013 Leukemia, 2013
- Join now to see all
Clinical Trials
- Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2004 Jun 01
- Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia Start of enrollment: 2008 Sep 01
- A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 1695 citationsInternational Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaShaji Kumar, Bruno Paiva, Kenneth C. Anderson, Brian G.M. Durie, Ola Landgren
The Lancet. Oncology. 2016-08-01 - 207 citationsDaratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Hervé Avet-Loiseau, Tomer M Mark
Haematologica. 2018-12-01 - 30 citationsDaratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic riskKatja Weisel, Andrew Spencer, Suzanne Lentzsch, Hervé Avet-Loiseau, Tomer M Mark
Journal of Hematology & Oncology. 2020-08-20
Journal Articles
- Disrupted Radial and Tibial Microarchitecture in Patients with Monoclonal Gammopathy of Undetermined SignificanceE Shane, E M Stein, S Lentzsch, J Fu, Osteoporosis international
- Selinexor plus Low-Dose Bortezomib and Dexamethasone for Patients with Relapsed or Refractory Multiple MyelomaSuzanne Lentzsch, Cristina Gasparetto, Blood
- Beyond NEOD001 for Systemic Light-Chain AmyloidosisSuzanne Lentzsch, Cindy Varga, Blood
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple MyelomaSuzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple MyelomaSuzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Single Arm, Prospective, Open-Label Phase II Trial to Evaluate the Efficacy of Isatuximab in Patients with Monoclonal Gammopathy of Renal SignificanceSuzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Untangling Amyloidosis 201860th American Society of Hematology Annual Meeting - 11/30/2018
- Bone Disease in Multiple MyelomaENDO 2018: 100th Endocrine Society Annual Meeting - Chicago, Illinios - 03/17/2018
- What is Optimal maintenance therapy duration for a newly diagnosed multiple myeloma patients completing inductionNew York, NY - 1/1/2015
- Join now to see all
Other
- Treatment Combination Offers New Option for Patients with Advanced Multiple MyelomaSuzanne Lentzsch, UPMC Physician Resources
http://blogs.upmcphysicianresources.com/2011/treatment-combination-offers-new-option-for-patients-with-advanced-multiple-myeloma-upci-researchers-find/ - Multiple Myeloma and Bone DiseaseSuzanne Lentzsch, Wego Health
http://sharinghub.wegohealth.com/multiple-myeloma-and-your-bones/40-treating-multiple-myeloma-bone-disease - Managing Myeloma a Professional Resource for Multiple MyelomaSuzanne Lentzsch
http://www.managingmyeloma.com/knowledge-center/clinical-trials/highlighted-trials-2013/804-phase-ii-trial-with-elotuzumab-plus-lenalidomide-and-low-dose-dexamethasone-in - Join now to see all
Press Mentions
- Curative Approach to Smoldering Myeloma May Prevent ProgressionAugust 7th, 2024
- Zanubrutinib May Produce Better Outcomes Than Ibrutinib in Rel/Ref CLL, SLLDecember 5th, 2022
- Ibrutinib-Rituximab Wins Out in Waldenstrom's MacroglobulinemiaOctober 11th, 2021
- Join now to see all
Insurance Accepted
- CIGNA HMO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Healthfirst New York
HIP of New York - Select PPOMagnaCare PPO
Multiplan PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: